Instrument Inactif

Communiqués Nile Therapeutics, Inc. Other OTC

Actions

US6541451018

Recherche biotechnologique et médicale

Cours en clôture Other OTC
- ^USD	-

14/08	L'action Capricor s'envole : l'espoir renaît pour son traitement contre la myopathie de Duchenne après un signal de la FDA	RE
14/08	L'action Capricor Therapeutics s'envole de 98 % après l'accord de la FDA pour examiner un amendement au dossier du Deramiocel	MT

Communiqués

19/08	Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline	NE
17/08	Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline	NE
17/08	ATTENTION CAPR INVESTORS: Contact Berger Montague About a Capricor Therapeutics, Inc. Class Action Lawsuit	NE
14/08	Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline	NE
13/08	Capricor: Q2 Earnings Snapshot	AQ
13/08	Capricor Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update	AQ
13/08	Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline	NE
13/08	CAPR INVESTOR NOTICE: RGRD Law Announces that Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Capricor Class Action Lawsuit	AQ
12/08	CAPR INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit	BU
10/08	Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline	NE
10/08	Capricor Therapeutics to Report Second Quarter 2026 Financial Results and Provide Recent Corporate Update on August 13	AQ
07/08	Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline	NE
05/08	CAPR Robbins Geller Rudman & Dowd LLP Announces that Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit	BU
03/08	Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline	NE
01/08	Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline	BU
30/07	The Lancet Publishes HOPE-3 Data for Capricor Therapeutics Deramiocel in Duchenne Muscular Dystrophy	AQ
30/07	Capricor Therapeutics Provides Update on FDA Advisory Committee Meeting for Deramiocel	AQ
29/07	The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy	AQ
27/07	Capricor Comments on Briefing Materials Ahead of July 29 FDA Advisory Committee Meeting for Deramiocel	AQ
26/06	Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy	AQ
26/06	Capricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Annual Conference	AQ
08/06	Capricor Therapeutics to Present at Upcoming Investor Conferences	AQ
29/05	Capricor Therapeutics : Expands Commercial Leadership Team	PU
12/05	Capricor: Q1 Earnings Snapshot	AQ
12/05	Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update	AQ